Department of Radiation Oncology, University Hospital Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany.
Department of Gynecology and Obstetrics, University Hospital Münster, 48149, Münster, Germany.
Stem Cell Res Ther. 2022 May 26;13(1):212. doi: 10.1186/s13287-022-02891-3.
Endometrial carcinoma is the most common gynecological cancer in Europe. Musashi-1 is known to be a key regulator of endometrial cancer stem cells and a negative prognostic marker. In the present study, we aimed to understand growth and gene expression patterns in endometrial carcinoma after Musashi-1 knockdown in vitro and in vivo. Changes in therapeutic resistance were also assessed.
First, we performed analyses to understand Musashi-1 expression patterns using The Cancer Genome Atlas database. We then proceeded to assess effects of small interfering RNA-based Musashi-1 targeting in two endometrial carcinoma cell lines, Ishikawa and KLE. After quantifying baseline changes in cell metabolism, we used MTT tests to assess chemotherapy effects and colony formation assays to understand changes in radioresistance. For mechanistic study, we used quantitative polymerase chain reaction (qPCR) and western blotting of key Musashi-1 target genes and compared results to primary tissue database studies. Finally, xenograft experiments in a mouse model helped understand in vivo effects of Musashi-1 knockdown.
Musashi-1 is aberrantly expressed in primary tumor tissues. In vitro, silencing of Musashi-1 resulted in a strong decline in cell proliferation and radioresistance, while chemoresistance remained unchanged. Loss of Musashi-1 led to downregulation of telomerase, DNA-dependent protein kinase, the Notch pathway and overexpression of cyclin-dependent kinase inhibitor p21, the latter of which we identified as a key mediator of Msi-1 knockdown-related anti-proliferative signaling. In vivo, the anti-proliferative effect was confirmed, with Msi-1 knockdown tumors being about 40% reduced in size.
Musashi-1 knockdown resulted in a strong decrease in endometrial cancer proliferation and a loss of radioresistance, suggesting therapeutic potential.
子宫内膜癌是欧洲最常见的妇科癌症。Musashi-1 已知是子宫内膜癌干细胞的关键调节因子和负预后标志物。在本研究中,我们旨在了解 Musashi-1 敲低后体外和体内子宫内膜癌的生长和基因表达模式。还评估了治疗耐药性的变化。
首先,我们使用癌症基因组图谱数据库进行分析,以了解 Musashi-1 的表达模式。然后,我们评估了两种子宫内膜癌细胞系 Ishikawa 和 KLE 中基于小干扰 RNA 的 Musashi-1 靶向的效果。在量化细胞代谢的基线变化后,我们使用 MTT 试验评估化疗效果,并用集落形成试验了解放射抗性的变化。为了进行机制研究,我们使用定量聚合酶链反应(qPCR)和 Western 印迹检测关键 Musashi-1 靶基因,并将结果与原发性组织数据库研究进行比较。最后,在小鼠模型中的异种移植实验有助于了解 Musashi-1 敲低的体内效应。
Musashi-1 在原发性肿瘤组织中异常表达。在体外,沉默 Musashi-1 导致细胞增殖和放射抗性明显下降,而化疗耐药性保持不变。Musashi-1 的缺失导致端粒酶、DNA 依赖性蛋白激酶、Notch 通路下调和细胞周期蛋白依赖性激酶抑制剂 p21 的过表达,我们发现后者是 Msi-1 敲低相关抗增殖信号的关键介质。在体内,证实了抗增殖作用,Msi-1 敲低肿瘤的大小减少了约 40%。
Musashi-1 敲低导致子宫内膜癌增殖明显减少和放射抗性丧失,提示具有治疗潜力。